Veterinary Vaccine Adjuvants Sales

Veterinary Vaccine Adjuvants Sales Market Outlook

The Veterinary Vaccine Adjuvants market is expected to reach approximately USD 1.5 billion by 2035, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025-2035. This significant growth can be attributed to the rising incidence of infectious diseases among livestock and pets, coupled with an increasing focus on improving vaccine efficacy. The global demand for veterinary vaccine adjuvants is further fueled by the growing pet population and the expansion of aquaculture practices, prompting the need for effective immunization solutions. Innovations in adjuvant formulations are also paving the way for the development of novel veterinary vaccines, driving market growth as manufacturers seek to enhance the effectiveness of their products.

Growth Factor of the Market

The growth of the Veterinary Vaccine Adjuvants market is primarily driven by the increased prevalence of zoonotic diseases that can be transmitted from animals to humans. As consumer awareness regarding food safety and animal health rises, farmers and pet owners are more inclined to vaccinate their animals, boosting the demand for effective adjuvants. Moreover, advancements in veterinary medicine, including new formulations and delivery methods, are expected to enhance the efficacy of existing vaccines, further driving the need for innovative adjuvants that can improve immune responses. The growing trend of integrating technology into veterinary practices, such as telemedicine, is also likely to contribute to market growth as it allows for more accessible veterinary care, including vaccinations. Additionally, supportive government regulations and initiatives promoting animal health will further bolster the market for veterinary vaccine adjuvants.

Key Highlights of the Market

• The Veterinary Vaccine Adjuvants market is projected to reach USD 1.5 billion by 2035.
• 7.5% CAGR is anticipated during the forecast period from 2025 to 2035.
• Increasing incidence of infectious diseases among livestock and pets drives demand.
• Innovations in adjuvant formulations enhance vaccine efficacy.
• Rising awareness regarding food safety and animal health among consumers.

By Product Type

Mineral Salt Adjuvants:

Mineral salt adjuvants are widely utilized in veterinary vaccines due to their ability to enhance the immune response. These adjuvants primarily consist of compounds like aluminum salts, which are known for their safety and effectiveness. By stimulating a stronger immune response, mineral salt adjuvants help in the production of antibodies, thereby increasing the overall efficacy of vaccines. Their role in prolonging antigen exposure in the immune system is particularly valuable, leading to better protection against diseases. As a result, mineral salt adjuvants are favored in both livestock and companion animal vaccines, contributing significantly to the overall growth of the market.

Oil Emulsion Adjuvants:

Oil emulsion adjuvants are increasingly recognized for their ability to provide sustained immunogenic responses in veterinary vaccines. These adjuvants are characterized by their capacity to create a depot effect, releasing the antigen slowly over time, which enhances the duration and intensity of the immune response. The versatility of oil emulsion adjuvants allows for their application across various types of vaccines, particularly in livestock and poultry. Moreover, as the industry moves towards more effective and durable vaccines, the demand for oil emulsion adjuvants is projected to rise, driving growth in this segment.

Liposome Adjuvants:

Liposome adjuvants represent an innovative approach in the formulation of veterinary vaccines, offering several advantages including improved antigen delivery and enhanced safety profiles. These adjuvants encapsulate antigens within lipid bilayers, which facilitates increased uptake by immune cells. Liposome adjuvants are particularly beneficial in eliciting both humoral and cellular immune responses, making them suitable for a variety of applications, from livestock to companion animals. As research continues to uncover the mechanisms by which liposome adjuvants enhance vaccine efficacy, their adoption in the veterinary sector is expected to expand significantly.

Carbohydrate Adjuvants:

Carbohydrate adjuvants, also known as immunomodulators, play a crucial role in enhancing the immune response of veterinary vaccines by stimulating innate immunity. These adjuvants can be derived from various natural sources and are known for their ability to improve the immunogenicity of antigens. Their application is particularly useful in vaccines targeting viral pathogens, making them essential for the prevention of diseases in both livestock and companion animals. The growing interest in natural and biodegradable adjuvants is expected to drive the market for carbohydrate adjuvants in the coming years.

Polymer Adjuvants:

Polymer adjuvants are gaining popularity in the veterinary vaccine market due to their unique properties that allow for controlled release of antigens and enhanced immune responses. These adjuvants can be engineered to provide specific immune modulation and are often used in conjunction with other adjuvant types to optimize vaccine formulation. Their adaptability and potential for customization make polymer adjuvants attractive for developing next-generation veterinary vaccines. As the demand for advanced vaccination strategies increases, the role of polymer adjuvants is expected to expand significantly.

By Application

Livestock Vaccines:

Livestock vaccines represent a significant portion of the veterinary vaccine adjuvants market, driven by the need for disease prevention and control in animals raised for food production. The increasing global demand for animal protein and the need to ensure food safety are prompting farmers to adopt vaccination programs for their livestock. Effective use of adjuvants in these vaccines is critical for enhancing the immune response, thereby minimizing the incidence of infectious diseases. Moreover, government regulations regarding animal health and the welfare of livestock further support the growth of this application segment.

Companion Animal Vaccines:

The companion animal vaccines segment is witnessing substantial growth, driven by the rising pet ownership and the increasing awareness of pet health. Owners are becoming more proactive in ensuring their pets receive vaccinations against preventable diseases, which is leading to a higher demand for effective veterinary vaccine adjuvants. As the market continues to evolve, manufacturers are focusing on developing vaccines with improved safety and efficacy, leveraging the use of adjuvants to enhance immune responses in companion animals. This trend is expected to significantly contribute to the overall growth of the market.

Aquaculture Vaccines:

The aquaculture vaccines segment is becoming increasingly important due to the rapid expansion of aquaculture practices worldwide. As fish farming becomes a more prominent source of protein, the need for effective vaccines to prevent infectious diseases in aquatic species is paramount. The application of adjuvants in aquaculture vaccines helps to boost the immune response, ensuring that fish are adequately protected against diseases that can impact production. As the industry scales, the use of innovative adjuvant technologies tailored to aquatic species is likely to drive growth in this market segment.

Poultry Vaccines:

Poultry vaccines are a critical area within the veterinary vaccine adjuvants market, particularly due to the significant economic impact of avian diseases on the poultry industry. Effective vaccination programs supported by robust adjuvant formulations are essential for maintaining poultry health and preventing outbreaks of diseases such as avian influenza. The growing global poultry production necessitates the use of vaccines that can effectively enhance immune responses, driving demand for adjuvants in this application segment. As poultry farming continues to expand, the need for advanced vaccine technologies will further propel the market.

Others:

This category encompasses various applications of veterinary vaccines that do not fall under the primary segments of livestock, companion animals, aquaculture, or poultry. These may include vaccines for exotic pets, wildlife, and zoo animals, each presenting unique challenges in vaccine development. The use of adjuvants in these specialized vaccines is essential for ensuring effective immune responses, especially in species that may not respond as predictably as traditional livestock or pets. As awareness grows about the importance of animal health across all species, the demand for adjuvanted vaccines in these niche markets is anticipated to increase.

By Distribution Channel

Veterinary Hospitals:

Veterinary hospitals play a pivotal role in the distribution of veterinary vaccine adjuvants, offering comprehensive healthcare services for a variety of animal species. These facilities are often equipped with advanced technology and staffed by trained professionals who ensure the proper administration of vaccines. As such, they serve as critical points for the delivery of veterinary vaccines, including those that utilize adjuvants to optimize immune responses. The trust that pet owners place in veterinary hospitals, combined with the growing trend of preventive care, is expected to bolster the demand for vaccine adjuvants distributed through this channel.

Veterinary Clinics:

Veterinary clinics, which typically cater to a more localized clientele, also represent a significant distribution channel for veterinary vaccine adjuvants. These clinics often focus on companion animals and play a crucial role in educating pet owners about the importance of vaccinations and the benefits of adjuvanted vaccines. With the increase in pet ownership and the emphasis on regular veterinary check-ups, clinics are well-positioned to drive the demand for vaccine adjuvants. Furthermore, the personalized approach offered by veterinary clinics enhances client loyalty and promotes repeat business, contributing positively to the overall market landscape.

Online Pharmacies:

The rise of e-commerce has led to the emergence of online pharmacies as a vital distribution channel for veterinary vaccine adjuvants. Pet owners increasingly seek convenience and efficiency when purchasing veterinary products, and online pharmacies provide a platform for easy access to a wide range of vaccine options. This trend is particularly beneficial for those in remote areas who may have limited access to veterinary services. As online purchasing continues to grow in popularity, the demand for adjuvanted vaccines available through this channel is expected to witness significant increases.

Retail Pharmacies:

Retail pharmacies are becoming important distribution outlets for veterinary vaccine adjuvants, as they provide pet owners with easy access to essential veterinary medicines. Many retail pharmacies are now offering a selection of veterinary vaccines that include adjuvants, catering to the needs of pet owners who prefer to obtain medications from a familiar source. The expansion of retail pharmacy services, including walk-in clinics and vaccination services, enables greater outreach and education about the importance of vaccinations. This trend contributes to the overall growth of the veterinary vaccine adjuvants market, as more consumers recognize the significance of vaccinating their animals.

Others:

The 'Others' category includes various distribution channels that facilitate the availability of veterinary vaccine adjuvants. These may encompass direct sales from manufacturers to veterinary practices, as well as regional distributors that supply veterinary products in specific areas. The diversity of distribution channels in this segment underscores the importance of accessibility for pet owners and veterinarians alike. As demand for veterinary vaccine adjuvants continues to rise, new channels may emerge to cater to the evolving landscape of veterinary healthcare.

By Ingredient Type

Aluminum Salts:

Aluminum salts are among the most commonly used adjuvants in veterinary vaccines, known for their ability to enhance the immune response while maintaining a favorable safety profile. These compounds work by creating a depot effect at the site of injection, allowing for prolonged antigen release and stimulation of an immune response. The established track record of aluminum salts in both human and veterinary medicine has contributed to their widespread acceptance. Their regulatory approval and effectiveness make aluminum salts a preferred choice for many veterinary vaccine formulations.

Squalene Emulsion:

Squalene emulsion is gaining traction as an adjuvant in veterinary vaccines due to its immunostimulatory properties and its ability to enhance the efficacy of vaccines. Derived from natural sources, squalene is recognized for its safety and compatibility with various vaccine formulations. The use of squalene emulsion in veterinary medicine not only improves the immune response but also reduces the need for higher doses of antigens, making vaccine production more cost-effective. As the industry shifts towards more sustainable and effective solutions, the demand for squalene emulsion is anticipated to grow significantly.

Liposomes:

Liposomes serve as innovative delivery systems and adjuvants in veterinary vaccines, providing targeted release and enhanced immunogenicity. The encapsulation of antigens within liposomes facilitates their uptake by immune cells, leading to a more robust immune response. This ingredient type is particularly valuable in the development of vaccines for complex pathogens, as it allows for the induction of both humoral and cellular immunity. As research continues to unveil the benefits of liposome-based formulations, their adoption in veterinary vaccines is expected to accelerate.

Freund's Adjuvant:

Freund's adjuvant is a well-established ingredient used in veterinary vaccine formulations, known for its ability to induce strong immune responses. Comprising a mixture of oil and water, Freund's adjuvant can enhance the efficacy of vaccines by providing a sustained release of antigens. While its use is more restricted due to potential side effects, it remains valuable in research and certain veterinary applications where a robust immune response is essential. The continued exploration of Freund's adjuvant in specific contexts may lead to its moderated use in future veterinary vaccine formulations.

MPLA:

MPLA, or monophosphoryl lipid A, is an ingredient that has garnered attention for its potential as a safe and effective adjuvant in veterinary vaccines. It functions as a toll-like receptor 4 (TLR4) agonist, enhancing the immune response without the adverse effects associated with traditional adjuvants. Its ability to induce a strong Th1-type immune response is particularly beneficial for combating infectious diseases in veterinary settings. As the search for safer adjuvants continues, the incorporation of MPLA in veterinary vaccine formulations is expected to grow.

By Region

The North American region is anticipated to dominate the Veterinary Vaccine Adjuvants market due to the presence of a well-established veterinary healthcare system and a high level of awareness about animal health. The region's increasing pet ownership and livestock farming activities contribute significantly to the demand for effective vaccines and adjuvants. With an estimated market share of over 40%, North America is projected to grow at a CAGR of 7% during the forecast period. The integration of advanced veterinary practices, coupled with stringent regulations regarding animal health, is expected to further enhance market growth in this region.

Europe is also a significant player in the Veterinary Vaccine Adjuvants market, driven by a strong focus on animal welfare and food safety regulations. The European Union has implemented strict guidelines to ensure that vaccines and adjuvants used in veterinary medicine are safe and effective. The European market is expected to grow at a CAGR of 6.5%, with a projected share of around 30% of the global market. The increasing prevalence of infectious diseases in livestock and pets is prompting governments and farmers to invest in vaccination programs, further bolstering the demand for veterinary vaccine adjuvants.

Opportunities

As the Veterinary Vaccine Adjuvants market continues to evolve, several opportunities present themselves for manufacturers and stakeholders. One notable opportunity lies in the development of novel adjuvant formulations that cater to the specific needs of various animal species. With an increasing focus on personalized veterinary medicine, the creation of tailored vaccines that utilize innovative adjuvants can enhance the immunogenicity of vaccines and address the unique challenges presented by different pathogens. Additionally, as the global demand for animal protein rises, there is an increasing need for effective vaccination strategies in livestock, opening up avenues for the expansion of adjuvant applications in this sector.

Furthermore, collaborations and partnerships between veterinary pharmaceutical companies and research institutions can foster innovation and lead to the discovery of new adjuvant technologies. By investing in research and development, companies can tap into emerging trends such as the use of nanotechnology and biocompatible materials in adjuvant formulations. The increasing awareness among pet owners regarding the importance of vaccinations also presents opportunities for growth in the companion animal segment. By leveraging marketing strategies that emphasize the benefits of adjuvanted vaccines, companies can effectively reach this target audience and expand their market share.

Threats

Despite the promising growth prospects, the Veterinary Vaccine Adjuvants market faces several threats that may impede progress. One of the primary challenges is the increasing regulatory scrutiny surrounding veterinary products, including vaccines and adjuvants. As regulatory agencies impose stricter guidelines for safety and efficacy, manufacturers may face delays in product approvals and increased compliance costs. This could potentially slow down the pace of innovation and limit the introduction of new adjuvants into the market, thereby affecting overall growth.

Moreover, the presence of alternative vaccination strategies, such as DNA vaccines and live-attenuated vaccines, may pose a threat to the traditional vaccine adjuvants market. As advancements in biotechnology continue to emerge, these alternatives may offer effective solutions without the need for conventional adjuvants. Consequently, manufacturers of veterinary vaccine adjuvants must continuously innovate and demonstrate the advantages of their formulations to maintain competitiveness in a rapidly changing landscape.

Competitor Outlook

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Ceva Sante Animale
• Virbac
• Vetoquinol
• Heska Corporation
• Hipra
• Merial (now part of Boehringer Ingelheim)
• IDT Biologika
• Phibro Animal Health Corporation
• Neogen Corporation
• Genus plc
• Alltech

The competitive landscape of the Veterinary Vaccine Adjuvants market is characterized by a diverse array of companies that are actively engaged in the research, development, and marketing of veterinary vaccines and adjuvants. Major players in this sector include global pharmaceutical giants such as Zoetis Inc. and Merck Animal Health, which have established robust product portfolios and strong distribution networks. These companies leverage their resources to invest in research and development, focusing on the creation of innovative vaccine formulations that incorporate advanced adjuvants to enhance efficacy and safety.

In addition to established players, several smaller firms and specialized biotech companies are entering the Veterinary Vaccine Adjuvants market, contributing to a competitive environment characterized by innovation and differentiation. Companies like Ceva Sante Animale and Virbac are increasingly focusing on expanding their product offerings and reaching niche markets within the sector. This growing competition drives continuous improvement in the quality and performance of veterinary vaccine adjuvants, ultimately benefiting animal health outcomes.

Furthermore, partnerships and collaborations among key stakeholders, including research institutions and veterinary professionals, are fostering advancements in adjuvant technologies. For instance, companies that engage in joint research initiatives are likely to uncover new insights into the mechanisms of action of adjuvants, leading to the development of more effective vaccine formulations. This collaborative approach not only accelerates product development but also enhances the scientific credibility of the adjuvants in the veterinary market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Hipra
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Virbac
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Alltech
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Genus plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Vetoquinol
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Zoetis Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 IDT Biologika
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Heska Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Ceva Sante Animale
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Neogen Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Merck Animal Health
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Elanco Animal Health
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Phibro Animal Health Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Merial (now part of Boehringer Ingelheim)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Veterinary Vaccine Adjuvants Sales Market, By Application
    • 6.1.1 Livestock Vaccines
    • 6.1.2 Companion Animal Vaccines
    • 6.1.3 Aquaculture Vaccines
    • 6.1.4 Poultry Vaccines
    • 6.1.5 Others
  • 6.2 Veterinary Vaccine Adjuvants Sales Market, By Product Type
    • 6.2.1 Mineral Salt Adjuvants
    • 6.2.2 Oil Emulsion Adjuvants
    • 6.2.3 Liposome Adjuvants
    • 6.2.4 Carbohydrate Adjuvants
    • 6.2.5 Polymer Adjuvants
  • 6.3 Veterinary Vaccine Adjuvants Sales Market, By Ingredient Type
    • 6.3.1 Aluminum Salts
    • 6.3.2 Squalene Emulsion
    • 6.3.3 Liposomes
    • 6.3.4 Freund's Adjuvant
    • 6.3.5 MPLA
  • 6.4 Veterinary Vaccine Adjuvants Sales Market, By Distribution Channel
    • 6.4.1 Veterinary Hospitals
    • 6.4.2 Veterinary Clinics
    • 6.4.3 Online Pharmacies
    • 6.4.4 Retail Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Veterinary Vaccine Adjuvants Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Veterinary Vaccine Adjuvants Sales market is categorized based on

By Product Type

• Mineral Salt Adjuvants
• Oil Emulsion Adjuvants
• Liposome Adjuvants
• Carbohydrate Adjuvants
• Polymer Adjuvants

By Application

• Livestock Vaccines
• Companion Animal Vaccines
• Aquaculture Vaccines
• Poultry Vaccines
• Others

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Online Pharmacies
• Retail Pharmacies
• Others

By Ingredient Type

• Aluminum Salts
• Squalene Emulsion
• Liposomes
• Freund's Adjuvant
• MPLA

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Ceva Sante Animale
• Virbac
• Vetoquinol
• Heska Corporation
• Hipra
• Merial (now part of Boehringer Ingelheim)
• IDT Biologika
• Phibro Animal Health Corporation
• Neogen Corporation
• Genus plc
• Alltech